• China Shineway Pharmaceutical turnover fell 28.3% year-over-year to RMB 1.73 billion for the nine months ended September 30, 2026.
• TCM formula granule turnover declined 30.8% to RMB 503 million.
• Injection product turnover dropped 39.2% to RMB 478 million.
• Granule product turnover decreased 10.1% to RMB 351 million.
• Soft capsule turnover fell 14.3% to RMB 289 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Shineway Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261106-12403299), on November 06, 2026, and is solely responsible for the information contained therein.